IP Library Granted Patent US 8,954,153
Granted Patent B2
US 8,954,153 · App. 12/653,023 · Granted Feb 10, 2015

Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,954,153
App. No.
12/653,023
Granted
Feb 10, 2015
Kind
B2
Abstract

It has been discovered that pain felt in a given region of the body can be treated, not by motor point stimulation of muscle in the local region where pain is felt, but by stimulating muscle close to a “nerve of passage” in a region that is superior (i.e., cranial or upstream toward the spinal column) to the region where pain is felt. Spinal nerves such as the intercostal nerves or nerves passing through a nerve plexus, which comprise trunks that divide by divisions and/or cords into branches, comprise “nerves of passage.”

Claims (39)

1. A method to reduce and/or relieve pain in a targeted painful region comprising:

activating a peripheral nerve innervating the targeted painful region with an intramuscular lead inserted into muscle tissue near the peripheral nerve and outside of the targeted painful region and evoking a tingling sensation over at least a portion of the targeted painful region without damaging the peripheral nerve.

2. The method according to claim 1 , wherein the intramuscular lead being inserted into muscle tissue near the peripheral nerve comprises the intramuscular lead being inserted into muscle tissue in electrical proximity to the nerve of passage.

3. The method according to claim 1 , further comprising delivering a test stimulation through the intramuscular lead and observing a muscle response.

4. The method according to claim 1 , wherein evoking the tingling sensation includes applying an electrical stimulation to the peripheral nerve during or after the insertion of the intramuscular lead and determining whether the electrical stimulation of the peripheral nerve generates the tingling sensation over the at least a portion of the targeted painful region.

5. The method according to claim 1 , wherein the intramuscular lead is removable from the muscle tissue by pulling the intramuscular lead from the muscle tissue.

6. The method according to claim 1 , wherein a duration of the evoking the tingling sensation ranges from approximately minutes to a plurality of years.

7. The method according to claim 6 , wherein the duration ranges from approximately one week to twelve weeks.

8. The method according to claim 1 , wherein patient feedback is not required to position the intramuscular lead to evoke the tingling sensation.

9. The method of claim 1 , wherein the intramuscular lead is inserted without surgery.

10. The method of claim 1 , wherein the intramuscular lead is spaced from the peripheral nerve while being in electrical proximity to the nerve of passage.

11. The method of claim 1 , wherein the intramuscular lead is configured to withstand mechanical forces and resist migration during the evoking of the tingling sensation.

12. The method of claim 1 , wherein the intramuscular lead enables movement of a joint during the evoking of the tingling sensation.

13. The method according to claim 1 , wherein the lead is inserted into muscle tissue upstream of the targeted pain area.

14. A method to alleviate pain comprising:

identifying a tissue region including skeletal muscle innervated by a peripheral nerve innervating a targeted painful region,

placing at least one electrode within the tissue region near the peripheral nerve outside of the painful region, and

applying stimulation to the at least one electrode according to predefined therapeutic stimulation parameters to activate the peripheral nerve and provide therapeutic nerve stimulation that evokes a tingling sensation to alleviate pain in the targeted painful region without functional nerve stimulation at a motor point and without damaging the peripheral nerve.

15. A method according to claim 14

wherein the peripheral nerve includes a peripheral nerve passing through a nerve plexus.

16. A method according to claim 15

wherein the peripheral nerve includes a peripheral nerve passing through at least one of a brachial plexus, lumbar plexus, sacral plexus, and cervical plexus.

17. A method according to claim 14

wherein the peripheral nerve includes at least one of a femoral nerve, sciatic nerve, radial nerve, median nerve, ulnar nerve, and an intercostal nerve.

18. The method according to claim 14 , wherein placing the at least one electrode is checked or guided by an imaging technique.

19. The method according to claim 18 , wherein the imaging technique includes at least one of ultrasound, fluoroscopy, and X-ray.

20. The method according to claim 14 , wherein placing the at least one electrode includes percutaneously inserting a lead in the muscle tissue or adipose tissue in electrical proximity to but spaced away from the peripheral nerve.

21. The method of claim 20 , wherein the lead includes a coiled fine wire electrode lead.

22. The method of claim 21 , wherein the coiled fine-wire electrode lead is configured to withstand mechanical forces and resist migration during long-term use.

23. The method of claim 14 , wherein placing the at least one electrode is guided by a patient's report of the tingling sensation.

24. The method of claim 23 , wherein the patient's report of the tingling sensation indicates confirmation of placement of the at least one electrode to alleviate the pain in the targeted painful region.

25. The method of claim 14 , wherein a response of at least one muscle in the tissue region guides the placing of the at least one electrode.

26. The method of claim 14 , wherein the placing of the at least one electrode is upstream of a joint of a patient and free of interference with the joint.

27. The method of claim 14 , wherein the applying stimulation to the at least one electrode is accomplished for a therapeutic amount of time whereby the alleviation of pain in the targeted painful region lasts for a time longer than the therapeutic amount of time.

28. The method of claim 14 , wherein the targeted painful region includes an incision from surgery and the at least one electrode is placed remote from the incision.

29. The method of claim 14 , wherein the placing of the at least one electrode within the tissue region is accomplished in less than 10 minutes by a clinician.

30. The method of claim 14 , wherein the peripheral nerve includes a nerve trunk.

31. The method of claim 30 , wherein activating the nerve trunk alleviates the pain in the targeted painful region.

32. The method according to claim 14 , wherein the electrode is placed remote from and upstream of the targeted pain area.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066416/0282 →
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066416/0526 →
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066526/0025 →
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066415/0750 →
RELEASE OF SECURITY INTEREST Recorded Feb 8, 2024
From: THE DIRECTOR OF DEVELOPMENT, STATE OF OHIO, FORMERLY KNOWN AS THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC., FORMERLY KNOWN AS SPR THERAPEUTICS, LLC
Reel/Frame 066416/0420 →
SECURITY INTEREST Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: GEMINO HEALTHCARE FINANCE, LLC
Reel/Frame 066412/0400 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 066381/0075 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTIES LISTED IN THE SECURITY INTEREST PREVIOUSLY RECORDED AT REEL: 030518 FRAME: 0830. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 10, 2020
From: SPR THERAPEUTICS, LLC
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 052137/0516 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0721 →
RELEASE OF SECURITY INTEREST Recorded Oct 15, 2019
From: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
To: SPR THERAPEUTICS, INC.
Reel/Frame 050728/0676 →
CHANGE OF NAME Recorded Dec 6, 2017
From: SPR THERAPEUTICS, LLC
To: SPR THERAPEUTICS, INC.
Reel/Frame 044716/0812 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044414/0575 →
SECURITY INTEREST Recorded Nov 9, 2017
From: SPR THERAPEUTICS, INC.
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 044715/0395 →
SECURITY INTEREST Recorded Sep 24, 2014
From: SPR THERAPEUTICS, LLC
To: OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 033809/0771 →
SECURITY AGREEMENT Recorded May 30, 2013
From: SPR THERAPEUTICS, LLC
To: THE DIRECTOR OF THE OHIO DEVELOPMENT SERVICES AGENCY
Reel/Frame 030518/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2010
From: BOGGS, II, JOSEPH W.
To: NDI MEDICAL, LLC
Reel/Frame 024002/0582 →